Amarin (AMRN) Surges Following Statistically Significant Study of AMR101

April 18, 2011 7:43 AM EDT Send to a Friend
Shares of Amarin Corporation plc (Nasdaq: AMRN) are jumping 70 percent higher this morning after the company announced statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

Amarin said triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the predefined non-inferiority b.

Link to full release.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Hot FDA News, Momentum Movers

Add Your Comment